Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the July 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the July 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Sarepta Therapeutics, Inc. (SRPT) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...

In addition to specific proprietary factors, Trade-Ideas identified Sarepta Therapeutics as such a stock due to the following factors: SRPT has an average dollar-volume (as measured by average ...